Last reviewed · How we verify
HES 130/0.4
HES 130/0.4 is a synthetic colloid that expands intravascular volume by maintaining oncotic pressure in the bloodstream.
HES 130/0.4 is a synthetic colloid that expands intravascular volume by maintaining oncotic pressure in the bloodstream. Used for Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma.
At a glance
| Generic name | HES 130/0.4 |
|---|---|
| Sponsor | University Hospital, Clermont-Ferrand |
| Drug class | Synthetic colloid / Plasma volume expander |
| Modality | Biologic |
| Therapeutic area | Critical Care / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Hydroxyethyl starch (HES) 130/0.4 is a plasma volume expander composed of glucose polymers with a molecular weight of 130 kDa and degree of substitution of 0.4. It functions as a colloid, remaining in the intravascular space longer than crystalloids to restore and maintain circulating blood volume during acute blood loss or hypovolemia. The molecule exerts oncotic pressure that draws and retains fluid within blood vessels.
Approved indications
- Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma
Common side effects
- Acute kidney injury
- Coagulopathy / increased bleeding
- Hyperchloremic acidosis
- Anaphylactic reactions
Key clinical trials
- Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch (HES) Fluid Therapy
- Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications (PHASE4)
- Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR Patients (NA)
- Cardiac Output in Preeclamptic (NA)
- Optimizing Fluid Resuscitation in Adults With Major Burns: A Randomized Trial of Burn Navigator™ Versus Parkland Formula (PHASE4)
- Priming of Cardiopulmonary Bypass With Hydroxyethyl Starch 130/0.4 or Sodium Chloride 0.9% : Pilot Study in Adult Elective Conventional Cardiac Surgery (PHASE3)
- Colloid Infusion for Optimal Outcomes In Non-cardiac Surgery (COIN Trial) (NA)
- Mild ANH on Pre-bypass Coagulation Function During Cardiac Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HES 130/0.4 CI brief — competitive landscape report
- HES 130/0.4 updates RSS · CI watch RSS
- University Hospital, Clermont-Ferrand portfolio CI